Skip to main content

Table 1 Characteristics of included studies

From: Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis

Study

Year

Country

Study period

Follow-up duration (months)

Median age (range), years

No.of patients

TNM staging

End points

Study design

Histology

Treatment

Raja M. Flores et al.[36]

2006

USA

1998–2005

24

67 (35–85)

137

0–4

OS

P

Epithelioid

Mixed

Sarcomatoid

Surgery

Adem Koyuncu et al. [28]

2015

Turkey

2008–2012

50

53.6 ± 10.6

60

1–4

OS

R

Epithelial

Biphasic

Undifferentiated

Multimodality therapy

Chemotherapy

Best supportive care

C E Hooper et al.[31]

2015

UK

2008–2011

12

65–80

73

1–4

OS

P

Epithelioid

Biphasic

Sarcomatoid

Chemotherapy

Andrea Billé et al.[29]

2016

USA

2000–2013

1.2(0–68.2)

71 (46–90)

191

1–4

OS

R

Epithelioid

Biphasic

Sarcomatoid

Non-specified

Chemotherapy

Radiotherapy

Palliative

Ozlem Ozmen et al.[28]

2016

Turkey

2009–2013

2.7–4.7

56.2 (28–80)

51

1–4

OS

R

Epithelial

Biphasic Sarcomatoid

Unidentified

Best supportive care

Chemotherapy

Multimodality therapy

Pleuropneumonectomy

Pleurectomy/decortication

David O. Hall et al.[32]

2017

UK

2008–2011

30

69–80

73

1–4

OS

P

Epithelioid Sarcomatoid

Biphasic

chemotherapy

Kazuhiro Kitajima et al. [29]

2017

Japan

2007–2014

15(1–96)

66(31–84)

201

1–4

OS

R

Epithelial

Sarcomatoid

Biphasic

Desmoplastic

Others

Non Surgery Group Chemotherapy

Chemotherapy and RT

Berna Akıncı Özyürek et al. [30]

2018

Turkey

2006–2014

60

56.1 ± 11.4

73

1–4

OS

R

Epithelial

Biphasic

Chemotherapy

Chemotherapy-Pallative radiotherapy

chemotherapy

Hiroshi Doi et al. [25]

2019

Japan

2006–2015

24

68(31–84)

188

1–4

OS

R

Epithelioid

Non-epithelioid

Chemotherapy

radiotherapy

Filippo Lococo et al. [23]

2020

Italy

2009–2018

84

69 ± 9

141

1–4

OS

R

Epithelial

Biphasic

Sarcomatoid

Surgery

Chemotherapy

Jun Hyeok Lim et al.[33]

2020

Korea

2009 -2018

8.7(3.8–21.9)

64 (53–71)

54

1–4

OS

R

Epithelioid

Sarcomatoid

Biphasic

NOS

Surgery

Chemotherapy

Bülent Mustafa Yenigün et al. [22]

2021

Turkey

2008–2018

13 (4–55)

60 (39–84)

65

1–4

OS

R

Epithelioid

Sarcomatoid

Biphasic

Malignant pleural mesothelioma

Chemotherapy

surgery

  1. NA not available, R retrospective, P prospective, OS overall survival, RT radiotherapy, ET endocrine therapy